WO2010133941A3 - New hybrid particles and their use in diagnostics and therapy - Google Patents

New hybrid particles and their use in diagnostics and therapy Download PDF

Info

Publication number
WO2010133941A3
WO2010133941A3 PCT/IB2010/001145 IB2010001145W WO2010133941A3 WO 2010133941 A3 WO2010133941 A3 WO 2010133941A3 IB 2010001145 W IB2010001145 W IB 2010001145W WO 2010133941 A3 WO2010133941 A3 WO 2010133941A3
Authority
WO
WIPO (PCT)
Prior art keywords
diagnostics
therapy
hybrid particles
new hybrid
diagnosis
Prior art date
Application number
PCT/IB2010/001145
Other languages
French (fr)
Other versions
WO2010133941A2 (en
Inventor
Loredana Latterini
Fausto Elisei
Luigi Tarpani
Original Assignee
Universita Degli Studi Di Perugia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita Degli Studi Di Perugia filed Critical Universita Degli Studi Di Perugia
Publication of WO2010133941A2 publication Critical patent/WO2010133941A2/en
Publication of WO2010133941A3 publication Critical patent/WO2010133941A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0026—Acridine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention concerns new particles which can be used in the diagnosis and treatment of some pathologies, in particular nanoparticles for use in the diagnosis and treatment of tumours, and their use and the compositions that contain them.
PCT/IB2010/001145 2009-05-20 2010-05-17 New hybrid particles and their use in diagnostics and therapy WO2010133941A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2009A000887A IT1394302B1 (en) 2009-05-20 2009-05-20 "NEW HYBRID PARTICLES AND THEIR USE IN DIAGNOSIS AND THERAPY"
ITMI2009A000887 2009-05-20

Publications (2)

Publication Number Publication Date
WO2010133941A2 WO2010133941A2 (en) 2010-11-25
WO2010133941A3 true WO2010133941A3 (en) 2011-01-13

Family

ID=41506422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/001145 WO2010133941A2 (en) 2009-05-20 2010-05-17 New hybrid particles and their use in diagnostics and therapy

Country Status (2)

Country Link
IT (1) IT1394302B1 (en)
WO (1) WO2010133941A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025513A2 (en) * 2003-09-12 2005-03-24 The Regents Of The Univeristy Of California Guanidinium derivatives for improved cellular transport
WO2006102307A2 (en) * 2005-03-21 2006-09-28 University Of Louisville Research Foundation, Inc. Target specific nanoparticles for enhancing optical contrast enhancement and inducing target-specific hyperthermia
WO2008140624A2 (en) * 2006-12-22 2008-11-20 The Board Of Regents Of The University Of Texas System Methods and compositions related to hybird nanoparticles
WO2009032752A2 (en) * 2007-08-28 2009-03-12 University Of Florida Research Foundation, Inc. Multimodal nanoparticles for non-invasive bio-imaging

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005025513A2 (en) * 2003-09-12 2005-03-24 The Regents Of The Univeristy Of California Guanidinium derivatives for improved cellular transport
WO2006102307A2 (en) * 2005-03-21 2006-09-28 University Of Louisville Research Foundation, Inc. Target specific nanoparticles for enhancing optical contrast enhancement and inducing target-specific hyperthermia
WO2008140624A2 (en) * 2006-12-22 2008-11-20 The Board Of Regents Of The University Of Texas System Methods and compositions related to hybird nanoparticles
WO2009032752A2 (en) * 2007-08-28 2009-03-12 University Of Florida Research Foundation, Inc. Multimodal nanoparticles for non-invasive bio-imaging

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KANDPAL D. ET AL.: "Synthesis and characterization of silica-gold core-shell (SiO2@Au) nanoparticles.", PRAMANA -J. PHYS., vol. 69, no. 2, 1 August 2007 (2007-08-01), pages 277 - 283, XP007911186 *
LEOPOLD K ET AL.: "Gold-Coated Silica as a preconcentration phase for the determination of total dissolved mercury in natural waters using atomic fluorescence spectrometry", ANAL CHEM., vol. 81, no. 9, 1 May 2009 (2009-05-01), XP007911176 *

Also Published As

Publication number Publication date
IT1394302B1 (en) 2012-06-06
ITMI20090887A1 (en) 2010-11-21
WO2010133941A2 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
HK1216880A1 (en) Certain triazolopyridines, compositions thereof and their use in the treatment of cancer.
IL261338B (en) Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
HK1199099A1 (en) Methods and compositions for the treatment and diagnosis of cancer
MX2011007930A (en) Crystalline insulin-conjugates.
ZA201205432B (en) Compositions and methods for the diagnosis and treatment of tumor
EP4324527A3 (en) Formulations of enzalutamide
ZA201207377B (en) Composition comprising probiotic bacteria for use in the treatment of immune disorders
MX2019000225A (en) Compositions and methods for treatment of autoimmune and other disease.
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
RS20140202A1 (en) Biospecific immunibinders directed against tnf and il-17
AP2011005672A0 (en) Pyrazolopyrimidines and their use for the treatment of CNS disorders.
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
EP2480687A4 (en) Methods and compositions for the diagnosis and treatment of thyroid cancer
IL237649B (en) Polymeric prodrug for use in the diagnosis, prevention and treatment of diseases of the joint
WO2010083385A3 (en) Compounds for reducing drug resistance and uses thereof
EP2723924A4 (en) Methods and compositions for the treatment and diagnosis of cancer
HK1197276A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
MX356755B (en) Fumigillol type compounds and methods of making and using same.
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2013081645A3 (en) Erbb3 mutations in cancer
HK1203190A1 (en) Compounds for use in imaging, diagnosing and or treatment of diseases of the central nervous system
EP2361317A4 (en) Use of eif3m for the diagnosis and treatment of cancer
WO2011047011A3 (en) Treatment and diagnosis of inflammatory disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10730507

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10730507

Country of ref document: EP

Kind code of ref document: A2